News coverage about The Medicines Company (NASDAQ:MDCO) has been trending somewhat positive this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. The Medicines Company earned a daily sentiment score of 0.23 on AlphaOne’s scale. AlphaOne also gave news articles about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:
- The Medicines Company (MDCO) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Investor Focus on Shares of The Medicines Company (NASDAQ:MDCO) – Jonesboro Recorder (jonesbororecorder.com)
- A Technical Strategy for Ashland Global Holdings Inc. (ASH), The Medicines Company (MDCO) – AllStockNews (allstocknews.com)
- Fizzle or Sizzle? What’s Behind the Numbers For The Medicines Company (NasdaqGS:MDCO) – Stock Talker (thestocktalker.com)
A number of research firms have issued reports on MDCO. ValuEngine raised shares of The Medicines Company from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. CIBC set a $50.00 price objective on shares of The Medicines Company in a report on Tuesday, May 23rd. Oppenheimer Holdings, Inc. began coverage on shares of The Medicines Company in a report on Monday, May 22nd. They set a “market perform” rating and a $50.00 price objective on the stock. Cowen and Company lifted their price objective on shares of The Medicines Company from $39.00 to $61.00 and gave the stock an “outperform” rating in a report on Wednesday, April 19th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $62.00 price objective on shares of The Medicines Company in a report on Wednesday, April 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The Medicines Company has an average rating of “Buy” and a consensus target price of $54.40.
Shares of The Medicines Company (NASDAQ:MDCO) opened at 37.09 on Friday. The stock’s 50 day moving average price is $42.64 and its 200-day moving average price is $43.88. The company’s market capitalization is $2.64 billion. The Medicines Company has a 1-year low of $30.80 and a 1-year high of $55.95.
The Medicines Company (NASDAQ:MDCO) last released its earnings results on Wednesday, April 26th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by $0.31. The Medicines Company had a negative return on equity of 19.09% and a negative net margin of 91.25%. The company had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $37.76 million. During the same period in the prior year, the company posted ($1.03) earnings per share. The company’s revenue was down 51.9% on a year-over-year basis. On average, equities analysts predict that The Medicines Company will post ($5.97) EPS for the current year.
The Medicines Company Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2230044/the-medicines-company-mdco-getting-somewhat-positive-press-coverage-study-shows.html
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.